Under construction – not a live service
Sign in
Taking people in IndiaPhase 3

Tests efruxifermin in adults with cirrhosis caused by fatty liver disease

Tests efruxifermin against a placebo in adults with cirrhosis from MASH.

Plain-language title generated from the registry record
Registry title: A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

Key facts

Where
Chandigarh, Coimbatore, Hyderabad, Jaipur, Kolkata, Ludhiana, Mumbai, Mysore, Nagpur, New Delhi, Pune, Rishikesh, Surat, Thiruvananthapuram, Vadodara, and Varanasi, IndiaSee the 16 sites
Phase
Phase 3

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 80 with compensated cirrhosis (advanced liver scarring) caused by NASH/MASH, a fatty liver disease.

Age
18 to 80 years
Sex
All sexes can join.
Disease stage
Compensated cirrhosis (fibrosis stage 4) due to NASH/MASH. Cohort 1 needs a biopsy and a NAS score of 3 or more, or fatty liver plus 2 current features of metabolic comorbidities. Cohort 2 can be diagnosed by biopsy or by non-invasive tests.

Main reasons for not taking part

  • Another cause of liver disease
  • Type 1 diabetes
  • Unstable Type 2 diabetes
  • Any current or past decompensated liver disease

Read by machine on 12 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Source: NCT06528314, who can take part

Where in India

  • Chandigarh, PunjabHospital not named in the registryContact: Akero Site 1908Taking people
  • Coimbatore, Tamil NaduHospital not named in the registryContact: Akero Site 1920Taking people
  • Hyderabad, TelanganaHospital not named in the registryContact: Akero Site 1929Taking people
  • Jaipur, RajasthanHospital not named in the registryContact: Akero Site 1903Taking people
  • Kolkata, West BengalHospital not named in the registryContact: Akero Site 1914Taking people
  • Ludhiana, PunjabHospital not named in the registryContact: Akero Site 1928Taking people
  • Mumbai, MaharashtraHospital not named in the registryContact: Akero Site 1931Taking people
  • Mysore, KarnatakaHospital not named in the registryContact: Akero Site 1930Taking people
  • Nagpur, MaharashtraHospital not named in the registryContact: Akero Site 1909Taking people
  • New Delhi, National Capital Territory of DelhiHospital not named in the registryContact: Akero Site 1924Taking people
  • Pune, MaharashtraHospital not named in the registryContact: Akero Study DirectorNo longer taking part
  • Rishikesh, UttarakhandHospital not named in the registryContact: Akero Site 1923Taking people
  • Surat, GujaratHospital not named in the registryContact: Akero Study DirectorNo longer taking part
  • Thiruvananthapuram, KeralaHospital not named in the registryContact: Akero Site 1922Taking people
  • Vadodara, GujaratHospital not named in the registryContact: Akero Study DirectorNo longer taking part
  • Varanasi, Uttar PradeshHospital not named in the registryContact: Akero Site 1919Taking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Akero Therapeutics, Inc
Trial code
NCT06528314
Record updated
12 November 2026
Original description
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.Read full original descriptionShow less

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.

Inclusion: Cohort 1: Biopsy proven compensated cirrhosis (fibrosis stage 4) due to NASH/MASH and NAS score of >=3 (at least 1 in each category) or evidence of steatosis and 2 current features of metabolic comorbidities; Cohort 2: Biopsy proven or non-invasively diagnosed compensated cirrhosis (fibrosis stage 4) due to NASH/MASH.

Exclusion: Any current or prior history of decompensated liver disease; Other inclusion and exclusion criteria may apply; Type 1 diabetes or unstable Type 2 diabetes; Other causes of liver disease based on medical history and/or liver histology and/or central laboratory results.

ClinicalTrials.gov NCT06528314